OpGen buys AdvanDx
Newly public OpGen Inc. is buying fellow molecular diagnostics firm AdvanDx Inc., issuing 682k common shares valued at $2.4mm.
- In Vitro Diagnostics
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Full Acquisition
- Includes Contract
- Payment Includes Stock
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.